MedPath

University of Alberta

University of Alberta logo
🇨🇦Canada
Ownership
Private
Established
1908-01-01
Employees
10K
Market Cap
-
Website
http://www.ualberta.ca

The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane

Phase 2
Completed
Conditions
Rotator Cuff Injury
Anesthesia; Functional
Interventions
Drug: Normal saline
First Posted Date
2018-05-23
Last Posted Date
2022-05-24
Lead Sponsor
University of Alberta
Target Recruit Count
27
Registration Number
NCT03533452
Locations
🇨🇦

Sturgeon Community Hospital, St. Albert, Alberta, Canada

🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Phase 4
Terminated
Conditions
HIV-1-infection
Interventions
Drug: B/F/TAF
Drug: B/F/TAF Placebo
First Posted Date
2018-05-22
Last Posted Date
2022-12-14
Lead Sponsor
University of Alberta
Target Recruit Count
28
Registration Number
NCT03532425
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes

Not Applicable
Completed
Conditions
Atherosclerosis
Complications of Diabetes Mellitus
Interventions
Radiation: 18Fluoride-Sodium Fluoride radio-isotope
First Posted Date
2018-05-21
Last Posted Date
2018-05-21
Lead Sponsor
University of Alberta
Target Recruit Count
98
Registration Number
NCT03530176
Locations
🇨🇦

University Hospital of Alberta, Edmonton, Alberta, Canada

Motivation to Change Lifestyle Habits in Youth With Obesity

Completed
Conditions
Pediatric Obesity
Motivational Interviewing
First Posted Date
2018-05-17
Last Posted Date
2022-05-31
Lead Sponsor
University of Alberta
Target Recruit Count
54
Registration Number
NCT03527394
Locations
🇨🇦

Stollery Children's Hospital (Pediatric Centre for Weight and Health), Edmonton, Alberta, Canada

🇨🇦

Alberta Children's Hospital (Pediatric Centre for Weight and Health), Calgary, Alberta, Canada

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure

Phase 2
Completed
Conditions
Congestive Heart Failure Chronic
Interventions
Drug: Placebo
First Posted Date
2018-05-15
Last Posted Date
2023-01-12
Lead Sponsor
University of Alberta
Target Recruit Count
13
Registration Number
NCT03525379
Locations
🇨🇦

Alberta Cardiovascular and Stroke Research Centre, Edmonton, Alberta, Canada

Doxycycline to Protect Heart Muscle After Heart Attacks

Phase 2
Recruiting
Conditions
Heart Failure
ST Segment Elevation Myocardial Infarction
Interventions
First Posted Date
2018-04-25
Last Posted Date
2025-02-04
Lead Sponsor
University of Alberta
Target Recruit Count
170
Registration Number
NCT03508232
Locations
🇨🇦

Royal Alexandra Hospital, Edmonton, Alberta, Canada

Rewilding the Human Gut: Reintroduction of the Species Limosilactobacillus Reuteri

Not Applicable
Completed
Conditions
Microbial Colonization
Interventions
Other: L. Reuteri DSM20016T Strain
Other: Placebo
Other: L Reuteri PB-W1 Strain
Other: Non-Industrialized-Type Diet
First Posted Date
2018-04-18
Last Posted Date
2022-08-11
Lead Sponsor
University of Alberta
Target Recruit Count
30
Registration Number
NCT03501082
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Music Use for Sedation In Critically Ill Children

Not Applicable
Completed
Conditions
Music Therapy
Analgesia
Ventilators, Mechanical
Critical Care
Interventions
Other: Music
First Posted Date
2018-04-13
Last Posted Date
2019-05-13
Lead Sponsor
University of Alberta
Target Recruit Count
60
Registration Number
NCT03497559
Locations
🇨🇦

Stollery Children's Hospital, Edmonton, Alberta, Canada

Lixiana Acute Stroke Evaluation Registry

Phase 4
Completed
Conditions
Ischemic Stroke
Atrial Fibrillation
Hemorrhagic Transformation Stroke
Interventions
First Posted Date
2018-04-11
Last Posted Date
2024-04-05
Lead Sponsor
University of Alberta
Target Recruit Count
70
Registration Number
NCT03494530
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.

Phase 2
Completed
Conditions
Obesity
Metabolic Syndrome
Interventions
Biological: Placebo FMT
Biological: FMT
Dietary Supplement: Prebiotic Fiber
Dietary Supplement: Cellulose
First Posted Date
2018-03-27
Last Posted Date
2022-01-05
Lead Sponsor
University of Alberta
Target Recruit Count
68
Registration Number
NCT03477916
Locations
🇨🇦

Royal Alexandra Hospital, Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath